Oliceridine injection, our lead product candidate with FDA Breakthrough Therapy Designation, is a next generation IV analgesic in development for the management of moderate-to-severe acute pain.
Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary platform.
August 2, 2018Trevena Reports Second Quarter 2018 Financial Results
Copyright © Trevena, Inc.